NCCN 2025 Updates: Lung, Pancreatic and Breast Cancer
Reading tools
Sources
In this article
NCCN 2025 Updates — Lung (NSCLC), Pancreatic and Breast Cancer
Summary
6 Key Messages for 2025
- NSCLC/EGFR(+): Osimertinib + platinum/pemetrexed outperforms monotherapy in final OS; amivantamab + lazertinib is a strong chemotherapy-free alternative.
- Stage III EGFR(+): Consolidation osimertinib after chemoradiotherapy stands out with data supporting a new standard.
- Lung Cancer Screening: Age ≥50 & ≥20 pack-years and nodule-management pathways were updated/reinforced.
- Pancreatic Cancer: NALIRIFOX offers a first-line OS advantage; borderline resectable disease has stronger support for neoadjuvant treatment.
- Breast Cancer (HR+/HER2- mBC): Dato‑DXd has superior PFS but neutral OS in 2nd line → sequencing and toxicity management are crucial.
- Early-Stage HR+/HER2-: Adjuvant abemaciclib + ET has stronger recommendations following an OS signal.
Lung Cancer — NSCLC (EGFR Focus)
1) Two Strong 1st-Line Options
- Osimertinib + platinum/pemetrexed: Final OS 47.5 vs 37.6 months HR 0.77|p≈0.02.
- Amivantamab + lazertinib: Superior OS with a chemotherapy-free regimen; rash/IFR and paronychia require proactive skin care.
| Regimen | Outcome | Note |
|---|---|---|
| Osimertinib + platinum/pemetrexed | Median OS 47.5 months (vs 37.6) | Consistent across subgroups; monitor hematological toxicity |
| Amivantamab + lazertinib | Superior OS; ~60% survival at 3 years | Skin/epithelial toxicity, IFR premedication |
Practice: At baseline, brain MRI, NGS panel, QTc/drug interaction checks; during the first 8–12 weeks, hematological/liver/kidney monitoring should be frequent.
2) Stage III EGFR(+) — Consolidation Osimertinib
After definitive concurrent/sequential chemoradiotherapy, osimertinib produced substantially longer PFS; panel summaries are incorporating it as standard.
Implementation: Joint planning with radiation oncology, pneumonitis differential diagnosis, and scheduled chest CT and brain MRI.
3) Screening — NCCN 2025
Age ≥50 + ≥20 pack-years and LDCT nodule-management steps reinforced/updated.
Pancreatic Adenocarcinoma
1) First-Line Selection
| Regimen | Key Finding | Note |
|---|---|---|
| NALIRIFOX | OS 11.1 vs 9.2 months (Gem/nab-P); HR≈0.83 | Diarrhea/cholinergic toxicity; G-CSF threshold |
| FOLFIRINOX | Among preferred 1st-line options | For fit patients; neurotoxicity/diarrhea/marrow suppression |
| Gemcitabine + nab-paclitaxel | Often preferred with ECOG 2 | Monitor neuropathy; suitable for older/frail patients |
Genetic Testing: germline (BRCA1/2, PALB2) + somatic NGS — identify candidates early for PARP/experimental studies.
2) Stronger Support for Neoadjuvant Treatment
Borderline resectable cases showed neoadjuvant survival benefit (HR≈0.60) and R0 improvements. Multidisciplinary review and referral to high-volume centers are recommended.
Breast Cancer
1) HR+/HER2- Metastatic Disease — The Role of ADCs
- Datopotamab deruxtecan (Dato‑DXd): In 2L, superior PFS, neutral OS. Stomatitis and ocular monitoring are essential.
- Sacituzumab govitecan and T‑DXd require sequencing based on organ burden and prior response; ILD risk awareness is important.
Starting Kit: Oral care (salt/bicarbonate rinses), steroid-containing/alcohol-free mouthwashes; ocular symptoms warrant early ophthalmology review.
2) Early-Stage HR+/HER2- — Adjuvant CDK4/6
Abemaciclib + ET has shown an OS benefit ; treatment for suitable high-risk profiles is supported for 2 years .
Key Changes Compared with 2024
NSCLC (EGFR Focus)
| Topic | Before (≈2024) | Now (2025) | Practical Note |
|---|---|---|---|
| 1L EGFR(+) Systemic Treatment | Osimertinib monotherapy was preferred/Category 1. Combination OS data were unavailable. | Osimertinib + platinum/pemetrexed showed final OS superiority; the chemotherapy-free alternative amivantamab + lazertinib Category 1. | Combination for young/fit patients with high BM risk; prevent skin/IFR toxicity. |
| Stage III (After Chemoradiotherapy) | EGFR TKI was not routine; durvalumab was standard. | Consolidation osimertinib showed substantial PFS benefit and entered guidelines. | Pneumonitis vs TKI toxicity; brain MRI/CT schedules. |
| LDCT Screening Criteria | Age ≥50, ≥20 pack-years; nodule-management algorithms existed. | 2025 Insights updated/reinforced selection criteria and nodule pathways . | Update screening workflows. |
Pancreatic Cancer
| Topic | Before (≈2024) | Now (2025) | Practical Note |
|---|---|---|---|
| 1L Metastatic Regimens | FOLFIRINOX and Gem/nab‑P were the main options; NALIRIFOX was new. | NALIRIFOX became, with NAPOLI-3 OS/PFS and approvals, preferred/Category 1. | Choose FOLFIRINOX ↔ NALIRIFOX according to toxicity; manage G-CSF/diarrhea. |
| Borderline Resectable/LAPC | Neoadjuvant treatment was expanding, with heterogeneous practice. | Neoadjuvant treatment and high-volume centers gained emphasis; imaging/pathways were clarified. | Tumor board: neoadjuvant → surgery → adjuvant. |
Breast Cancer
| Topic | Before (≈2024) | Now (2025) | Practical Note |
|---|---|---|---|
| HR+/HER2− mBC (ADC) | ADC options were limited; Dato-DXd was not widely incorporated in guidelines. | Dato‑DXd became a 2nd-line option with superior PFS/neutral OS data, emphasizing stomatitis/ocular monitoring. | ADC sequencing after CDK4/6 and PARP (BRCA+). |
| Early-Stage HR+/HER2− (Adjuvant CDK4/6) | Abemaciclib evidence mainly covered DFS/DRFS; OS was immature. | An OS benefit was reported; suitable high-risk patients: 2 years of abemaciclib + ET. | Diarrhea/hematological monitoring and patient education. |
Sources
1. NCCN Guidelines® Insights — Akciğer Kanseri Taraması, 2025
2. LAURA Çalışması — NEJM 2024; özet ve yorumlar: Lung Cancer Today 2025
3. FLAURA2 Final OS — AstraZeneca PR 2025; ecancer 2025
4. MARIPOSA Final OS — NEJM 2025; sunum: ELCC 2025
5. NALIRIFOX (NAPOLI 3) — The Lancet 2023 (PubMed: 37708904)
6. Neoadjuvan (borderline rezeke) — Sistematik inceleme 2025
7. NCCN — Pankreas (Guidelines Detail); Meme (Guidelines Detail)
8. Dato DXd (TROPION Breast01) — JCO 2025; OS yorumu: Reuters 2024
9. Adjuvan Abemasiclib — NCCN atfı (Lilly HCP); haber: OncLive 2025
2. LAURA Çalışması — NEJM 2024; özet ve yorumlar: Lung Cancer Today 2025
3. FLAURA2 Final OS — AstraZeneca PR 2025; ecancer 2025
4. MARIPOSA Final OS — NEJM 2025; sunum: ELCC 2025
5. NALIRIFOX (NAPOLI 3) — The Lancet 2023 (PubMed: 37708904)
6. Neoadjuvan (borderline rezeke) — Sistematik inceleme 2025
7. NCCN — Pankreas (Guidelines Detail); Meme (Guidelines Detail)
8. Dato DXd (TROPION Breast01) — JCO 2025; OS yorumu: Reuters 2024
9. Adjuvan Abemasiclib — NCCN atfı (Lilly HCP); haber: OncLive 2025
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.